Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has provided an update.
Hemogenyx Pharmaceuticals has completed a capital reorganization involving the subdivision and reclassification of its shares, resulting in 3,504,539 new ordinary shares. The new shares are set to commence trading on the London Stock Exchange’s Main Market on December 13, 2024, following the reorganization’s approval at the recent Extraordinary General Meeting. The change in share structure and new ISIN is a strategic move to streamline the company’s capital structure, potentially impacting shareholder notifications under regulatory guidelines.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company headquartered in London with subsidiaries in New York City. It focuses on developing innovative therapies for blood and autoimmune diseases, including advancing bone marrow transplantation treatments. The company is working on various product candidates and platform technologies to address life-threatening diseases.
YTD Price Performance: -51.57%
Average Trading Volume: 13,552,833
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £15.62M
For detailed information about HEMO stock, go to TipRanks’ Stock Analysis page.
